Central and peripheral consequences of the chronic blockade of CB 1 cannabinoid receptor with rimonabant or taranabant

Journal of Neurochemistry

Volumn 112, Issue 5, 2010, Pages 1338-13351

  Martín García, Elena ^a   Burokas, Aurelijus ^a   Martín, Miquel ^a   Berrendero, Fernando ^a   Rubí, Blanca ^a   Kiesselbach, Christoph ^b   Heyne, Andrea ^b   Gispert, Juan Domingo ^c   Millán, Olga ^c   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b Medimod Pharmacology Services GmbH   (Germany)

^c Barcelona Biomedical Research Park   (Spain)

Author keywords

Autoradiography; Obesity; Rimonabant; Taranabant; Withdrawal

Indexed keywords

CANNABINOID 1 RECEPTOR; RIMONABANT; TARANABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; DIET; DRUG EFFECT; FAT CONTENT; FEMALE; LONG TERM CARE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR DENSITY; RECEPTOR INTRINSIC ACTIVITY; TREATMENT WITHDRAWAL; WEIGHT REDUCTION;

RATTUS;

EID: 75949122654     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06549.x     Document Type: Article

References (41)

1. Addy C., Wright H., Van Laere K. et al. (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 7, 68 78.
2. Akbas F., Gasteyger C., Sjodin A., Astrup A. Larsen T. M. (2009) A critical review of the cannabinoid receptor as a drug target for obesity management. Obes. Rev. 10, 58 67.
3. Bellocchio L., Mancini G., Vicennati V., Pasquali R. Pagotto U. (2006) Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr. Opin. Pharmacol. 6, 586 591.
4. Bellocchio L., Cervino C., Pasquali R. Pagotto U. (2008) The endocannabinoid system and energy metabolism. J. Neuroendocrinol. 20, 850 857.
5. Breivogel C. S. Sim-Selley L. J. (2009) Basic neuroanatomy and neuropharmacology of cannabinoids. Int. Rev. Psychiatry 21, 113 121.
6. Carai M. A., Colombo G. Gessa G. L. (2005) Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci. 77, 2339 2350.
7. Colombo G., Agabio R., Diaz G., Lobina C., Reali R. Gessa G. L. (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63, L113 L117.
8. Cota D. (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev. 23, 507 517.
9. Cota D., Marsicano G., Tschop M. et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423 431.
10. Despres J. P. (2007) The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit. Pathw. Cardiol. 6, 46 50.
11. Despres J. P., Golay A. Sjostrom L. (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121 2134.
12. Devane W. A., Dysarz F. A., III., Johnson M. R., Melvin L. S. Howlett A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605 613.
13. Di Marzo V. (2008) CB(1) receptor antagonism: biological basis for metabolic effects. Drug Discov. Today 13, 1026 1041.
14. Di Marzo V. (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 60, 77 84.
15. Di Marzo V. Matias I. (2005) Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8, 585 589.
16. Di Marzo V., Goparaju S. K., Wang L. et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822 825.
17. Fong T. M., Guan X. M., Marsh D. J. et al. (2007) Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)- 2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl] oxy]propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. 321, 1013 1022.
18. Hagmann W. K. (2008) The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch. Pharm. (Weinheim). 341, 405 411.
19. Hansen M. J., Schioth H. B. Morris M. J. (2005) Feeding responses to a melanocortin agonist and antagonist in obesity induced by a palatable high-fat diet. Brain Res. 1039, 137 145.
20. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R. Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563 583.
21. Heyne A., Kiesselbach C., Sahun I., McDonald J., Gaiffi M., Dierssen M. Wolffgramm J. (2009) An animal model of compulsive food-taking behaviour. Addict. Biol. 14, 373 383.
22. Howlett A. C., Bidaut-Russell M., Devane W. A., Melvin L. S., Johnson M. R. Herkenham M. (1990) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13, 420 423.
23. Kirkham T. C. (2008) Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies? Cell Metab. 7, 1 2.
24. Kirkham T. C., Williams C. M., Fezza F. Di Marzo V. (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136, 550 557.
25. Lange J. H. Kruse C. G. (2008) Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chem. Rec. 8, 156 168.
26. Matias I., Gonthier M. P., Orlando P. et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91, 3171 3180.
27. Pagotto U., Marsicano G., Cota D., Lutz B. Pasquali R. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27, 73 100.
28. Pi-Sunyer F. X., Aronne L. J., Heshmati H. M., Devin J. Rosenstock J. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761 775.
29. Ravinet T. C., Delgorge C., Menet C., Arnone M. Soubrie P. (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28, 640 648.
30. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G. Caput D. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240 244.
31. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Breliere J. C. Le Fur G. (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56, 1941 1947.
32. Schafer A., Pfrang J., Neumuller J., Fiedler S., Ertl G. Bauersachs J. (2008) The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br. J. Pharmacol. 154, 1047 1054.
33. Scheen A. J., Finer N., Hollander P., Jensen M. D. Van Gaal L. F. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368, 1660 1672.
34. Shafat A., Murray B. Rumsey D. (2009) Energy density in cafeteria diet induced hyperphagia in the rat. Appetite. 52, 34 38.
35. Sim L. J., Selley D. E. Childers S. R. (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. USA 92, 7242 7246.
36. Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O. Rossner S. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389 1397. (Pubitemid 40523733)
37. Van Gaal L. F., Pi-Sunyer X., Despres J. P., McCarthy C. Scheen A. 2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (Suppl. 2 S229 S240.
38. Vickers S. P. Kennett G. A. (2005) Cannabinoids and the regulation of ingestive behaviour. Curr. Drug Targets 6, 215 223.
39. Vickers S. P., Webster L. J., Wyatt A., Dourish C. T. Kennett G. A. (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167, 103 111.
40. Ward S. J. Dykstra L. A. (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav. Pharmacol. 16, 381 388.
41. Xie S., Furjanic M. A., Ferrara J. J. et al. (2007) The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J. Clin. Pharm. Ther. 32, 209 231.